Spots Global Cancer Trial Database for hr positive
Every month we try and update this database with for hr positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC | NCT04565054 | Breast Cancer F... | Abemaciclib 50 ... | 18 Years - | West German Study Group | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | NCT01288092 | Metastatic Brea... | BEZ235 | 18 Years - | Novartis | |
| Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer | NCT05025735 | Metastatic Brea... HER2-negative B... | Dapagliflozin 1... | 18 Years - 65 Years | Saint Luke's Health System | |
| Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer | NCT05025735 | Metastatic Brea... HER2-negative B... | Dapagliflozin 1... | 18 Years - 65 Years | Saint Luke's Health System | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | NCT01288092 | Metastatic Brea... | BEZ235 | 18 Years - | Novartis | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants | NCT05963984 | Metastatic Brea... Locally Advance... Breast Cancer | Samuraciclib Fulvestrant | 18 Years - | Carrick Therapeutics Limited | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC | NCT04055493 | Breast Cancer F... | Ribociclib 200M... | 18 Years - | West German Study Group | |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | NCT03671330 | Breast Cancer | Ribociclib Plac... Ribociclib NSAI: Letrozole... Letrozole Goserelin | 18 Years - 60 Years | Novartis | |
| A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | NCT05104866 | Breast Cancer | Dato-DXd Capecitabine Gemcitabine Eribulin Vinorelbine | 18 Years - | AstraZeneca | |
| Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | NCT04494425 | Advanced or Met... | Trastuzumab der... Capecitabine Paclitaxel Nab-Paclitaxel | 18 Years - 105 Years | AstraZeneca | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer | NCT06344780 | Breast Cancer | 18 Years - 75 Years | Fudan University | ||
| PRE-I-SPY Phase I/Ib Oncology Platform Program | NCT05868226 | HER2-positive B... Metastatic Canc... Metastatic Brea... Metastatic HER2-positive M... HER2 Mutation-R... HER-2 Protein O... HER2-negative B... Triple Negative... HR Positive Hormone Recepto... Estrogen Recept... Progesterone Re... Hormone Recepto... Solid Tumor Solid Tumor, Ad... Solid Carcinoma HER2 Low Breast... HER2 Low Breast... ER Positive Bre... PR-positive Bre... | ALX148 Fam-Trastuzumab... Zanidatamab Tucatinib | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | NCT04494425 | Advanced or Met... | Trastuzumab der... Capecitabine Paclitaxel Nab-Paclitaxel | 18 Years - 105 Years | AstraZeneca | |
| A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer | NCT05963997 | Metastatic Brea... Locally Advance... Breast Cancer | Samuraciclib Elacestrant Dih... | 18 Years - | Carrick Therapeutics Limited | |
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | NCT01953926 | Solid Tumors Ha... | Neratinib Fulvestrant Trastuzumab Paclitaxel | 18 Years - | Puma Biotechnology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
